Quinvaxem

Quinvaxem is a combined vaccine designed to protect infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b. This fully liquid vaccine is ready to use and contains diphtheria and tetanus toxoids, an inactivated whole cell pertussis component, hepatitis B surface antigen (HBsAg), and the H. influenzae type b component.

Key Information

• Indications: Quinvaxem is indicated for active immunization against diphtheria, tetanus, pertussis, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b.
• Administration: The primary vaccination involves three doses of 0.5 mL each, given at least one month apart, starting as early as six weeks of age. A booster dose of 0.5 mL is recommended for toddlers between 13 and 24 months after birth.
• Method of Administration: The vaccine is administered via intramuscular injection in the anterolateral thigh or deltoid region in children over 13 months.
• Contraindications: Quinvaxem should not be given to children with known hypersensitivity to any vaccine component, those who have shown signs of hypersensitivity after previous administration of similar vaccines, or those who have experienced an encephalopathy of unknown cause after a previous vaccination containing pertussis. Vaccination should also be postponed in children suffering from acute febrile illness.

Additional Details

• Manufacturer: Novartis.
• Country of Manufacture: Korea.
• Preservative: Thiomersal.
• Package Size: 1 dose.
• Pharmaceutical Form: Liquid.

Quinvaxem is a reliable choice for protecting infants and toddlers against serious infections. Its comprehensive protection makes it a crucial part of any childhood vaccination schedule.